Zynex, Inc. (ZYXI) Granted FDA Clearance for Blood Volume Monitor
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Zynex, Inc. (ZYXI) Tops Q4 EPS by 1c, Revenues Beat; Offers Q1 & FY20 Revenue Guidance Above Consensus
February 27, 2020 4:50 PM ESTZynex, Inc. (NASDAQ: ZYXI) reported Q4 EPS of $0.09, $0.01 better than the analyst estimate of $0.08. Revenue for the quarter came in at $14.2 million versus the consensus estimate of $13.77 million.
2019 Fourth Quarter
Revenue increased 52% year over year to $14.2 millionOrders increased 129%Net income of $2.9 million; Diluted EPS $0.09Adjusted EBITDA increased 30% to $4.1 millionFourteenth consecutive quarter of positive net incomeThomas Sandgaard, CEO said: "In the fourth quarter, we posted revenue of $14.2... More
Zynex Inc. (ZYXI) PT Raised to $19.75 at B.Riley/FBR
February 21, 2020 10:48 AM ESTB.Riley/FBR analyst Marc Wiesenberger raised the price target on Zynex Inc. (NASDAQ: ZYXI) to $19.75 (from $12.00) while maintaining a Buy rating.... More
